Management of prolactinomas during pregnancy

Area of Science:

• Endocrinology
• Reproductive Medicine
• Pharmacology

Background:

• Hyperprolactinemia is a frequent cause of infertility in women.
• Lowering prolactin (PRL) levels is crucial for restoring ovulation.
• Dopamine agonists are the primary pharmacologic treatment.

Purpose of the Study:

• To evaluate the safety and efficacy of dopamine agonists for hyperprolactinemia during pregnancy.
• To assess risks associated with pituitary adenoma growth during pregnancy.
• To provide guidance on managing hyperprolactinemia in pregnant women.

Main Methods:

• Review of existing literature on dopamine agonist use (bromocriptine, cabergoline) in pregnant women with hyperprolactinemia.
• Analysis of risks of pituitary adenoma enlargement with microadenomas and macroadenomas.
• Assessment of fetal outcomes associated with maternal dopamine agonist use.

Main Results:

• Cabergoline is slightly more effective than bromocriptine in lowering prolactin levels.
• Bromocriptine is considered safe for the fetus if discontinued early in pregnancy.
• Risk of adenoma growth is low (1%) for microadenomas but higher (23%) for macroadenomas if bromocriptine is stopped; continued bromocriptine or surgery are options for macroadenomas.
• Preliminary data suggest cabergoline use during pregnancy does not increase adverse fetal outcomes.

Conclusions:

• Dopamine agonists are effective treatments for hyperprolactinemia-induced infertility.
• Management strategies vary based on adenoma size, with options including drug discontinuation, continued treatment, or surgery.
• Current evidence supports the reasonable safety of continued cabergoline use during pregnancy, though further data are needed.